Why START? Reflections that led to the conduct of this large long-term strategic HIV trial

Jens Lundgren, Abdel Babiker, Fred Gordin, Sean Emery, Gerd Fätkenheuer, Jean Michel Molina, Robin Wood, James D. Neaton, Brian K. Agan, Beverly Alston-Smith, Alejandro Arenas-Pinto, Jose R. Arribas, Jason V. Baker, John Baxter, Waldo H. Belloso, Kate Brekke, Bruce Brew, Susan W. Brobst, William Burman, Cate CareyRichard Clark, David A. Cooper, Richard T. Davey, Guy De La Rosa, Eileen T. Denning, Matthew Dolan, Gregory Dore, Daniel Duprez, Ezekiel Emanuel, Christine Grady, Birgit Grund, Bernard Hirschel, Bruno Hoen, Fleur Hudson, Margaret A. Johnson, Chrispin Kambili, Karin Klingman, Ken M. Kunisaki, Alan Landay, Bruno Ledergerber, Sandra N. Lehrman, Ana Martinez, Sue Meger, Kelly Misar, Ronald T. Mitsuyasu, Amanda Mocroft, David Munroe, Michael Norton, Robert C. Palmer, Sarah L. Pett, Andrew Phillips, Deenan Pillay, Danielle Porter, Richard W. Price, Michael Proschan, Claire Rappoport, Peter Reiss, Boris Renjifo, Kevin Robertson, Jürgen Rockstroh, Gabriela Rodriguez, James F. Rooney, Michael J. Ross, Mauro Schechter, Siegfried Schwarze, Daniel Seekins, Shweta Sharma, Wendy Snowden, Amalio Telenti, Jeff Tryon, Jean van Wyk, Michael J. Vjecha, Edwina Wright

Research output: Contribution to journalEditorialpeer-review

27 Scopus citations
Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalHIV Medicine
Volume16
Issue numberS1
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Keywords

  • Antiretroviral therapy
  • CD4-guided ART
  • HIV
  • START trial
  • When to start

ASJC Scopus subject areas

  • Health Policy
  • Infectious Diseases
  • Pharmacology (medical)

Cite this